In short
Podcast Summary: CNBC's "Fast Money" - Nvidia Results On Deck… And RFK’s Impact On The Health Care Space (11/15/24)
Episode Overview This episode features a discussion led by Melissa Lee and a panel of expert traders on the upcoming financial results from Nvidia, current trends in the healthcare sector influenced by Robert F. Kennedy Jr.'s appointment, and broader market insights. The episode highlights key trading strategies and financial forecasts, alongside critical commentary on healthcare policies under the new administration.
Key Themes and Discussions
Nvidia's Upcoming Earnings
- Market Anticipation: Nvidia is set to report its third-quarter results, with analysts expressing high expectations.
- Price targets from various analysts range from $160 to $200, indicating a potential upside of about 40%.
- Panel Insights:
- Karen Feynman is cautious about high analyst expectations but is optimistic about Nvidia's long-term prospects, particularly regarding AI demand.
- Tim Seymour discusses the semiconductor industry's overall performance and Nvidia's unique position as a market leader.
- Julie Beal emphasizes the relationship between Nvidia's performance and Wall Street expectations, noting that a significant beat could lead to stock price volatility.
Concerns About Valuation and Market Sentiment
- Panelists express concern that the continuous upward revision of earnings expectations might set Nvidia up for a potential miss.
- Discussions revolve around Nvidia's market dominance and whether it can maintain its growth trajectory amid increasing competition.
Robert F. Kennedy Jr.'s Impact on Healthcare
- The announcement of RFK Jr. as the head of the Department of Health and Human Services has caused a significant decline in biotech and pharmaceutical stocks.
- Emerging figures in health policy, such as Casey and Callie Means, are scrutinized for their unconventional views on medicine and corporate influence in healthcare.
Panel Reactions
- Isabella Cueto from Stat News discusses the Means siblings' ideologies and their potential influence on drug approval processes.
- Concerns are raised about the implications of Kennedy's confirmation on the pharmaceutical industry, particularly regarding vaccine approvals and funding for the FDA.
Broader Market Commentary
- The episode touches on the performance of the S&P 500 and notable stocks such as Palantir, which is transitioning to the NASDAQ and is experiencing significant growth.
- The panel discusses the implications of rising Bitcoin prices, with Mark Yusko asserting a bullish outlook on Bitcoin's future as demand increases.
Upcoming Retail Earnings
- Anticipation surrounds the retail sector with key earnings reports from Walmart, Target, and others scheduled for the following week.
- Insights provided on consumer trends and spending behavior, especially as companies prepare for the holiday season.
Final Thoughts
- The episode concludes with traders sharing their final trades, reflecting on healthcare stocks, uranium investments, and the potential volatility in Nvidia shares.
Key Takeaways
- Nvidia's upcoming earnings report is a focal point, with high expectations leading to mixed sentiments among analysts.
- The potential impact of RFK Jr.'s health policies could reshape the healthcare landscape and influence investment strategies.
- Retail earnings scheduled for next week could reveal consumer sentiment as the holiday season approaches, affecting stock performance in the sector.
Conclusion This episode of "Fast Money" offers valuable insights into the current market dynamics surrounding Nvidia, the healthcare sector’s transformation under new leadership, and retail forecasts as the holiday season looms. The discussions underscore the interplay between market expectations, corporate performance, and broader economic trends.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:00Live from the Nasdaq market site in the heart of New York City's Times Square this is Fast The choice of health care, the little-known siblings that could emerge as a major force in the system under RFK Jr., what they could mean for medicine. Plus, Palantir marks a new milestone as it looks to transfer to the NASDAQ. The chartmaster says it is game on for the uranium trade, and it's fight night on Netflix. What tonight's big boxing match means for the streamer. I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Tim Seymour, Karen Feynman, Steve Grasso, and Julie Beal.
0:44We start off with two big stories on our radar. Crypto crushing it this week with Bitcoin back above the 91 ,000 mark and up 35 % since the election. More on that in a few minutes. But first, what else? NVIDIA. The AI darling gearing up to deliver third quarter results next week. And Wall Street is chomping at the bit for another strong report. Analysts upping their price targets on the chip giant ahead of Wednesday's results. Wedbush seeing the stock climbing to 160. Oppenheimer's at 175. Susquehanna, 180. And HSBC is all the way up at 200 bucks. That is 40 % upside from today's close. But can NVIDIA deliver another blowout quarter with expectations so high yet again?
1:25This is not the kind of action, Karen, that you love for one of your stocks going into earnings. Well, yes, I don't like the analyst action. I mean, the bar, just raise the bar, raise the bar, raise the bar. I do like the, you know, down kind of a lot. Yes, the pullback, not just today, but the last couple days. I think it hit 148 or 9 or something recently. And so I like that more. I think, you know, there's this sort of tension of the promise of AI and is it working and what will demand peak and then evidence to the contrary. And then you hear, you know, things like what was 100 ,000 chips today.
2:00Right. So I'm still optimistic on the story. I, you know, I am long. I don't have puts right now. So I don't know. I'll look at something. They're not going to be cheap, that's for sure. But I do think, though, going into the right before it, the skew will be toward the upside. The calls will be more expensive than the puts. So I'll look at that. But I'd rather have it be down a few days. Right. Tim? Well, if you look at the semiconductor group overall, they've been underperforming. NVIDIA has actually been really the stalwart in that space, and I think that's interesting. I get back to what seem to be the major drivers for the stock right now.
2:38Where are we on production with Blackwell? Where are we with hyperscalers and CapEx? We've heard we've had the earnings season where they've given some guidance. That guidance was fine. We've had some other read throughs from other folks that are part of kind of the chip infrastructure space, which hasn't been terribly good. And it gets back to where is the market and where is sentiment? That outperformance I'm talking about in the charts is notable. But I don't get the sense that the street is as keyed up into expectations on this number for some of the things, we've been talking about. And again, we have had the company be very clear to push back on any concerns around production side of it.
3:13So they can't really tell you how aggressively they see demand and they'll do a better job of that here. I'm sure we're not going to hear anything awful on demand. But I think it's a more balanced setup despite the run in the stock, because I just think expectations are lower. Eventually, they have to fail on earnings. Eventually, there's got to be something, right? You don't get to go into Vegas and keep betting on one thing and have the hand perform. But there's still 85 % of the market. Tim said it. Every other stock that you look at in the sector, the chart is horrendous. This is the... Go ahead.
3:52No, eventually you will miss. But I mean, is the miss a function of analysts getting too hyped up over it? And so therefore they're setting the stock up for a miss? If they didn't ratchet up their earnings expectations, they would easily jump over them. Without question. It's the context of that. It's a point of reference. It's where you're coming into it. So Karen's completely right. You would like them to talk it down. The problem is every time they've talked it down in the past, it's leaped over them. And they've looked silly. I'm sorry, when you're saying the analysts talk it down or the company?
4:22They don't really talk it. I'm saying it the wrong way. Whenever the analysts put out their estimates, they've definitely had a lower bar where NVIDIA leaps over it. And they've looked ridiculous. Because who should know? They should know how high that bar should be in theory. And whenever NVIDIA leaps over it, they look silly. So they keep raising the bar. So eventually NVIDIA has to fail. But it's going to be a beat and raise here. I mean, let's be clear. It's just a matter of the degree. It's a matter of the degree. But but again, I think it's it's really about Blackwell ramping and Hopper actually still growing.
5:02And I don't you know. Yeah. Yeah. Julie, I mean, you know, Jensen Huang has had multiple opportunities to sort of talk down Blackwell, talk down the demand, talk down the production issues, whatever. And not one opportunity was taken. Yeah, it sounds like he's very, very confident about the outlook. look, I think it's interesting to me in reading some of the research reports that we've been talking about. I read one today that was like, well, we expect them to beat by their usual$2 billion on the top line, which is an astronomic number just to beat by. I mean, as a small and mid-cap investor, I could only dream, right?
5:39But what I think is important is exactly what everyone is saying, which is this relationship between expectations and execution. And so far, they have been on the right side of that battle between those two. But when you have analysts just so regularly expecting this big beat and raise, it does create this challenge, this tightrope walk that they have to do. I think the demand is fine, and I think the production is fine. What I think is kind of an outstanding question for the long term, and this is where guidance will really come into play, is what is pricing going to look like over the longer term?
6:14We know that these hyperscalers are starting to recognize that they need to be able to create an economic model around this investment. And that's still a little bit uncertain. And so, you know, we kind of wait and see. So, I mean, I think I agree with the a beaten race, but a beaten race can still trade down. Right. We've seen that before. There's no there's no floor that's guaranteed under there. But Jensen-Wong, beside running this company and being at the forefront of AI, is also a master at expectations of Wall Street. And, you know, what else can he introduce? Remember, it was, well, we're going to have a new chip every year.
6:49That was something. Locking them in with the software. I mean, he's really good at sort of moving to the next chapter of the story. And we'll see if he does it again here. The bar is high for him. I mean, there's also, I mean, you mentioned the hyperscalers and their guidance, which does confirm the NVIDIA story. I mean, there's nothing that we got from the earnings report that leads us to believe that spending is in jeopardy for NVIDIA chips. There's also the other side of sovereign AI, which we haven't even talked about. I mean, I think as demand, demand in terms of all the sovereign money out there, particularly in the Middle East, who are going to build their own AI.
7:24I think that's important. I think we know that there is a kind of GPU demand is supply constrained here for cloud growth. It's just that simple. And so I think that's the story. But I do think it really is going to come down to what you're willing to pay for this company. And I think the growth is probably forget on a price to sales. But, you know, I think on a P.E. basis, I think there's something here that's actually at least defendable if you're out there right now. Long and video. Yeah, it looks like. Like, so it's hard not to be bullish on NVIDIA, right? We've been talking about this for a couple of minutes.
8:00It's hard not to be bullish on NVIDIA. But one of those days, it's not going to be a beat and raise. And to Karen's point, you can have a stock fall off. Time out. There we go. Look out, Steve. You sold NVIDIA right now. I feel like it was pulling me in. You sold NVIDIA. I did. Did you get back in? No, I might be waiting for a sell-off. You're the one. Get back in, Melissa. You are feeling like you missed it. Yes, I definitely missed it from 110 to where we're at right now. And you're waiting, and you're waiting for that sell-off to get back in. Let me ask you this. Let's say you had gotten back in at 112.
8:35What would you do right now? Sell? Yeah, I'd be a seller. That chart does look like it's rolling over. And when you start to see 80%, 85 % market share turn into 70%, 75%, I don't know if we're there yet. I think you've got to start saying, all right, maybe there's other opportunities. I want to get out of the way and have Julie pile on Steve, too, so all the ladies can really get after her. Come on in, pile on Steve. No, I agree. I mean, I absolutely agree. I think that's right. It's really, really hard to feel like this can continue forever into infinity. These gross rates are not sustainable forever, forever.
9:07I think, you know, we've owned in other portfolios NVIDIA for more than 10 years, right? And I think all of us at the firm are looking at this very large now position and wondering, what do we do with this, right? We recognize that it's a market leader. Our cost basis is very low. It's really hard to feel great for new clients coming in and buying our portfolios. They're buying at this price today. And that's where it starts to really not feel great as a portfolio manager. You really have to be thoughtful about, do I still feel great about the valuation right now? Would I buy this position right now?
9:41Have you trimmed at all your position in NVIDIA? Not in a long time. No, I haven't. I just made the bet. But, you know, but to Julie's point, you know, I always say if you went home long. Right. You bought it at this price. Sure. So I'm affirmatively saying, all right, I will continue to be long. Yeah. Yes. Right. Well, and if I can go out to four, I can go out to 25 and at least a couple of places that have put some some recent upgrades. And I can I can get a a low 30s P.E. multiple on a stock that I think is growing. We know about the growth. But I mean, again, I look within that peer group and NVIDIA doesn't feel expensive to me.
10:14So I would bring it back to valuation. I would bring it. It's not going to go on forever. But by 25, and certainly based upon the growth we're imputing until then, 32, 33 times. It works. All right. Our next guest is concerned about NVIDIA ahead of earnings. Mark Yusko is CEO and chief investment officer at Morgan Creek Capital Management. His firm is one point nine billion dollars in assets under management. Mark, always good to see you. As I understand it, Mark, you'd personally sell NVIDIA here. Why? Well, a couple of reasons. I mean, one, all the things that the crew was talking about. It's hard to stay on top when you're on top.
10:54I'm old enough to remember that Intel stock went up 20 fold over 10 years because their chip was going to revolutionize AI in 2000. And today, That stock is 63 % lower than it was 24 years ago. So you don't stay on top forever. And NVIDIA came along and invented GPU. And now we've got TPUs and VPUs and LPUs. So I think innovation will keep rolling. But the thing I'm most worried about with NVIDIA, their third largest customer is about to get delisted. That's a big story. So you're referring to Super Micro. Yes. Yes. So how does NVIDIA get caught up in this? Yes, Supermicro can be delisted. How does NVIDIA, how does that tarnish NVIDIA?
11:39Well, if it's your third largest customer and they actually haven't, they don't have the capacity to continue to be your third largest customer, what happens to your revenue growth and profits growth? You know, we've seen this move before with Nortel and Cisco back in 2000, 2001. So I don't know. That makes me nervous. Hi, Mark. It's Karen. Thanks for being on. I hear you. Let me just push back a little bit. To the extent that there is a supply constrainment here, not a demand constraint, right? So with the customers, if you look at what's happening to Dell and some others, there's the belief that those customers are going elsewhere and that that demand would still be there.
12:17Is that – do you – does that make sense? I think that's a great – that's a great story and possibly is true. Look, they're the third largest customer for a reason, and that's real for me. But I totally agree with you that there is a demand story today. I think the thing that's not being talked about enough is GPUs are really good for training. They're actually not really good for inference. Inference is the next level. So companies like Grok and others do. And the next layer of huge demand in semiconductors, I believe, is going to be for inference-focused chips, new designs, new innovations. And I think the tech debt at NVIDIA is going to cause some stress.
13:05Now, could they go out and buy some of these innovators and take over those markets too? Maybe. Hasn't historically been the way it's worked out for other people who are on top. But look, I'm a huge admirer of NVIDIA as a company. I think they have great products. I just think it's a little overpriced here. You make a pretty strong case against NVIDIA, Mark, but as you know, your clients still own it. So how do you, what's that conversation like when you're telling? Or what's the conversation going to be like on Monday when they start calling you saying, you said to sell because they're going to lose their third biggest customer and all sorts of other things.
13:43And it's in my portfolio. So a couple of things on that. One, you know, I spend most of my time now in venture capital. I do venture capital in the digital asset space. We own things like Bitcoin and companies like Coinbase. I still have a business that focuses on hedge funds and we allocate capital to hedge funds and then we supersize their 20 best ideas. So one of those 20 best ideas happens to be NVIDIA still. So it's a 5 % position in that half of the portfolio. And I trust the process. Those managers still have faith in it, just like a number of the people you were just talking to. If it were me and I were the portfolio manager, which I'm not, I would be a seller.
14:30But I trust the process on the other side of the house. Let's get to Bitcoin, since that is your core at this point in time, Mark. Where do you see it going here? It's above 91. And I think that's that's more than where you see it being a fair value. No, you know what I'm going to say? This is almost our five year anniversary, a little more than our five year anniversary of when we were together in 2019. And, you know, while I was on the show, I think Bitcoin crashed like 10 or 15 percent. And, you know, what should we do? I said, buy it. And you're like, well, you always say it. Well, no, I do buy it today, buy it tomorrow, buy it next week, buy it next month.
15:04I don't think you should buy it all at once. I think you should continue to accumulate the greatest, most powerful computing network the world has ever seen. And it is changing the nature of how we transact value. So I think that fair value today, as we're sitting here talking, is in the high 80s. So we're right around fair value. That fair value will continue to accrete as we go forward, as new people get involved. There's been a huge game changer in the last week. We now have a president-elect who has said he's pro-Bitcoin. He has Senator Lummis, who is amazing, saying that she's going to sponsor a bill to create a strategic Bitcoin reserve, and they want to accumulate 1 million Bitcoin.
15:49Let's just let that number hang there for a second. There are only 21 million that could ever exist. It's really closer to 18 million because there's about 3 million that have been lost or stolen. So you're talking about about six percent could be taken out of the supply. Plus, you have people like Michael Saylor going to raise$42 billion to buy more. So talk about unlimited demand and finite supply in the chip business. You can make more chips. In Bitcoin, there's only so many you can have. Yep. All right, Mark, good to see you. Thank you. Thanks, Melissa. Great to be with you. Mark Yusko, in case you didn't catch that graphic, he says 100K by Thanksgiving.
16:29That wouldn't shock me, actually. It does feel like there's this gravitational pull towards 100. It broke 90 the other day, traded back under, and I would have thought that's an opportunity for it to sell off it was really going to, and now it's right back up against there. So Thanksgiving, I don't know. How far are we away from Thanksgiving? Not far, like 10 days. I don't know. Gobble, gobble. But in that, call it some holiday this fall, this fall winter. I would not be surprised. All right, coming up, Palantir Pops, the soaring software giant, Right now, the top performing name in the S &P 500 this year.
16:59And that's not the only move it's making. The details next. Plus, it's fight night on Netflix. Mike Tyson takes on Jake Paul. What the bout will mean for live streaming on the platform. More Fast Money after this.
17:19Welcome back to Fast Money. Palantir jumping to a new all-time high today after announcing it will transfer its listing from the New York Stock Exchange to the Nasdaq on November 26. The company also expects that it will meet the eligibility requirements for the Nasdaq 100. Today's 11 % pop also rockets it past Vistra Energy, making it the best performer in the S &P 500 so far this year. NVIDIA is now all the way down at number three. But this is a huge jump after lots of huge jumps, particularly after its last earnings report. Yeah, believe it or not, I actually nibbled a little bit more today to a position I've been long and I can't justify the valuation at all.
17:57It's probably 35 times sales. It trades probably two times. Brent Hill, I'm looking at his note here. He says it trades two times what CrowdStrike trades at. So in terms of a multiple, in terms of a sales multiple. So I think it's a combination of the success they have going here. This is we're talking about, you know, three, maybe four, maybe even five successive quarters where they've shown pretty incredible growth. That's part of the story here. Part of it also is truly where they seem to have the inside track on some of the choices contracts in the world. And I do mean the government contracts.
18:29And I do mean the sense is that these are also some of the smartest guys in the room. So I hate the multiple. I've been lolling the name for some time. I actually traded out of it a little bit after second quarter earnings and lamented every bit of that. And I've been trying to get myself back to where I was. Well, they're getting two index boosts, right, because it was added to the S &P 500 in September and now to the Nasdaq 100. So there's a little bit of just the technical aspect of the run, Julie, but there's also the huge fundamental government contracts to mention, huge, but also the unrelenting demand for AI, which is what Alex Karp, the CEO, has talked about.
19:04I mean, that's a big part of this. Yeah, I think that's the narrative around that for everyone who missed out on NVIDIA. Everyone is looking for the opportunities around AI that have been overlooked. And this no longer is one of those plays. I would argue that there are probably plays that are better for AI than this. But what I think is in the note that Tim was referencing is in this valuation embedded is that this company can grow for several years at 40%, which is an acceleration from where it is right now, and still hold a 12 times sales multiple, which is high. That's a lot of good news that's priced in there.
19:40And so it's hard to feel confident saying, yeah, I would recommend stepping into this right now. I'm in the Julie Beal camp on this one as well. Let's think about, you know what didn't come up? The Department of Government Efficiency, Doge, didn't come up here. 56 % of their revenues is from the government. Do we think that revenue is going up or down or getting haggled? Do we have a person like Elon Musk who was a tech savvy guy? Is that where they're going to be cutting, though? I mean, I would think if anything, that's an area where Doge would say, hey, wave some more in. Or maybe you're doing it for X and maybe you've got to do it for X minus 20%.
20:16I don't know. It's just something. Things look pretty peachy when I look at the chart and all the aspects of it. That would be the headwind I'd be worrying about. I agree. I mean, I don't know that it's, you know, just the math. I can't get around. There's a lot of things where I can't get to the math and it ended up being great at every step of the way. But this is one that's, I mean, if you want to do the value play in video, I guess, relative to this. So that's for you. All right, coming up. Netflix is ready to rumble. The stakes for the streaming giants move into live sports as Mike Tyson and Jake Paul get ready for a major showdown in Texas.
20:49Plus, a brother and sister duo that could be about to shake up the American health care industry as RFK Jr. gears up to serve as health secretary under President Trump. The stakes for the biggest names in the space right after this. You're watching Fast Money Live from the NASDAQ Market Site. More after this quick break.
21:15Welcome back to Fast Money. Ring the bell. Former heavyweight world champion Iron Mike Tyson going fist to fist tonight with social media star turned boxer Jake Paul, 31 years his junior. The event marks Tyson's first professional fight in almost 20 years and has already broken the record for the biggest boxing gate outside of Las Vegas. No matter who comes out on top in the bout, Netflix shaping up to be the real winner. The fight is available to all of the streamers, 280 million plus subscribers for no additional fee. A welcome change for boxing fans who would usually have to shell out for pay per view.
21:47But this is, of course, one of Netflix's strategy, live sports, live entertainment, I guess is what they call it. They don't have to pay for rights and it can attract a lot of eyeballs. This is going to attract a lot of eyeballs. And they're doing this to putting a push into the NFL as well. And I think by not charging you something is the way to garner those eyeballs. We were talking about it. I would hope that you could see the fight at a normal time, not 11 or 12 o 'clock when they first come on. But I think this is a home run for Netflix. And it actually, when I look at the chart, you could have said this was Toppy months ago.
22:25If they can accrue some ad dollars based on this and the NFL and live sports, probably still worth a shot. Well, there's all that, plus the content slate. They've got season two of Squid Game. They've got this Keira Knightley series coming out, Black Dog. But this recent run, I think, is a lot on this. You know, I always buy the rumor, sell the news, and I always use the, all right, let's say a new Star Wars is coming out. The very next one, people get all excited. The box office is going to be gigantic. It almost doesn't matter how gigantic the box office is. Ultimately, it's a little disappointing.
22:54So I'm long. I'm not going to trade around it just because I think it's a little ahead of itself. But I think that's what's happened in the last ten days or so. Well, and I would argue that Star Wars has more fiction in it than this fight will. So, you know, it doesn't really matter. Again, this is entertainment. Call it what it is, that's what I'm going to call it. And I love the fact that Netflix is throwing themselves in the ring on this one. I do think that Christmas Day NFL football is a huge thing for Netflix. And I do think that they have multiple levers to pull. And, again, we don't even really talk all that much about gaming and some of the other dynamics.
23:25I think Netflix, when we and we spent a lot of time this week talking about a great week for Disney and a peculiar but extraordinary three year outlook that they gave with a lot of detail. And when I go out to 26 and I see Netflix making 30 bucks a share to Disney's 650 at probably half of the revenue. And so a much more profitable business that I think possibly has more scale. This is what you're excited about with Netflix. This is why the stock has moved. Doesn't mean I don't like Disney. I like the week Disney had. We're not talking about Disney. We're talking about Netflix. And it just gives you some sense on where they are in free cash flow and how far ahead.
Read the full transcript
24:02Well, you just self-would you rather. I'm going to oppose that question. Julie, you know, Disney having a week that was up 16 percent, Julie. Would you rather Netflix or Disney here? Still probably Netflix in this case. You know, like the way that I think about investing is I try to own the stocks that every other PM, it's the last thing that they want to sell. They'll hold on to this till the end. And Netflix is that for all of the streaming bundles. And I would say that even above Disney, which if you have kids, it's probably less likely. But events like this make it so much harder for people to just decide to dip out and cancel their subscription.
24:39So I think the stickiness of this kind of event is critical for the long term success and the valuation. All right. Coming up, a pair of siblings seem to have caught the attention of RFK Jr. what it could mean for the future of health care in this country and how they plan to make America healthy again, plus why the chart master says uranium giant Cameco is about to go nuclear, the technicals and the trade next.
25:05Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
25:22Welcome back to Fast Money. Stocks falling to close out the losing week as the post-election rally fades. The Dow dropping 305 points, the S &P falling 79 points, the Nasdaq tumbling nearly 2.25%. Meanwhile, shares of Chinese e-commerce giant Alibaba slipping even after seeing a nearly 60 % bump in earnings in its latest quarter. Sales growth coming in below expectations. And super micro shares with a late-day comeback to finish in the green. The one-time AI high flyer in danger of being delisted from the NASDAQ after missing the deadline to file its already delayed annual report. The stock now down more than 85 percent from its March peak.
25:59Karen, you got lured into the Supermicro store. You're out now, right? I'm out. You have no position. And I sold the puts when the stock was higher than you. Really? It really was. It was unusual. But, you know, we were talking that day. We're like, wow, this just the more you read this just sounds absurd. This is just really ridiculous. this. But so I don't know if there's some covering. I don't know. Certainly there's, you know, there's been a lot of money made to this point. Do you think they're really going to have a hard time getting, you know, they got to get an auditor. They got to get an auditor.
26:29There's that. There's that giant thing. A good one. Right. A decent, reputable one. That's going to be very hard. And then getting financials out. I mean, I think once they if they hire one, that will be good. But I don't have any sort of, I don't know, what's skin in the game here now or opinion at this level. Who knows? Right. Baba, Tim, this follows JD's earnings, which were also disappointing to some degree. It was a disappointing week to be invested in anything in China and to listen to some of the macro out of China. But I've always said that I think Baba is a bottom-up story and that I'm less concerned about the Chinese macro.
27:04I like the profitability. I do think they have levers to pull. I do want to hear more about asset sales. I want to hear spinoffs. I want to hear things that at least at times have been big drivers for this company. This is disappointing. I don't know that anyone who's been through the last couple of years in Baba and probably has traded it a little bit is feeling like today's announcement was a reason to give up the fight. I think the China story is going to make it harder to make money here. And I do think there's going to be more trading opportunities. But I think of myself as bolted, Baba. All right.
27:32A sea of red across the board for biotech, pharma and the broader health care sector. The moves follow last night's announcement that Donald Trump has tapped Robert F. Kennedy Jr. to lead the Department of Health and Human Services. And now two siblings who advise Kennedy are coming into the spotlight. Casey and Callie Means are chronic disease entrepreneurs known for questioning traditional medicine. They have medical expertise and they could play a key role in the next administration's health policy. Stat News' Isabella Cueto has been reporting on the Means sibling rise to prominence. She joins us now.
28:02Isabella, great to have you with us. Thanks for having me. Could we see one of the means is, you know, the heading CDC or FDA or any of the other sort of agencies within HHS? Well, there has there have been reports that Casey means may be on the list of considerations for the FDA. And so what is their how what is their connection to RFK Jr.? And do they share a lot of the same ideology? Some of it. How much overlap is there? I think there's quite a bit of overlap. I mean, these are really kind of RFK protégés. They have a disdain for corporate influence and regulation like big food and big pharma and think that there's a big conspiracy to keep Americans sick, and they want to address that.
28:52What do you think is the biggest, you know, you guys over at Stad have been talking to a lot of professionals, a lot of, you know, analysts, et cetera. What is the biggest concern about this ideology and what it could mean in terms of Medicare when it comes to drug approval? I mean, what is the one thing that sticks out? I think it's really the question of RFK. If he gets confirmed to be the secretary of health and human services, he would have broad oversight and could get in the way of drug approvals and make firewalls for pharmaceutical companies to jump over to get their drugs approved. In terms of the means, what have they done so far in the pursuit of this ideology?
29:37Some of their thoughts sort of align more to the left, actually, removing ultra-processed food from SNAP programs, things like that. So where do they fit in? I think that's really what they've been most successful at, is getting these talking points and ideas that are traditionally left, and then adding in a dose of outrage and making them Maha, make America healthy again, and aligned with MAGA. And so they've been on some of the biggest podcasts, Joe Rogan, Tucker Carlson, and really created this groundswell of support for the ideology, which was a big boon to the whole movement and to RFK specifically.
30:15Let's say the means has somehow worked their way into heading an agency in RFK as the head of HHS, Isabella. I'm just curious, you know, how quickly can the wheels turn in terms of actually putting some of that ideology to work? I think we don't know. I mean, I think it depends the people that they choose to surround themselves with and staff the agency with. I think if they decide to make staffing cuts, that could kind of gum up the wheels on some of the usual work that these agencies and departments do. But, you know, we're expected to get more indications soon. All right. Isabella, thanks so much for joining us.
30:52It was a fascinating profile of the means siblings. Thanks for sharing with us, Isabella Cueto. We saw a lot of reaction. IBB. I mean, across the board, vaccine makers. GSK got a downgrade from Deutsche Bank and it cited RFK Jr. I mean, that's the extent we're at right now. Yes. I mean, it's huge for, right, vaccine makers. For the IBB, which has, you know, it's biotech, but there's a lot of vaccine exposure. This, just since the four days ago, it's down 10 percent. This is an enormous move. It hasn't moved this much. We had one day in 2022, but since the pandemic, March of 2020, which ironically set up one of the great sort of vaccine runs for this space in a while.
31:39But this move is enormous. I'm long. This is painful. I'm not a seller here, though. You should be. My thought is you should be a buyer of anything that sold off on the RFK headline. First of all, we don't know if he's going to be confirmed. It's probably a better than 50-50. It's probably 60 % chance. He's also on record saying he's not totally anti-vax. No, he's okay with the ones that are already approved. It's just the ones that are coming in the pipeline might not make it. He said he wants a wealth of information out there. He said if vaccines work for you, and this is what he's just said on record the last couple of days, if vaccines work for you, I don't want to take them away from you.
32:18Right. But I want to make sure that everyone... The ones that are approved already. But I want to make sure everyone gets the right. But don't we want as much information as possible? Of course. But if you install people at the FDA who are skeptical of vaccines as well, it really means that the pipeline, if you're an mRNA, Moderna, let's say, and your bread and butter is vaccines and you're developing four other vaccines down the line for whatever it may be, even cancer, you know, those shots. One last thing. I know you want to go to Tim, but think about it. Think about who funds the FDA, right?
32:49That's a part of the means twins or whatever it is, siblings. So it's a part of it. They want to take the money out and they want it's a little incestual. Right. If you ever told somebody, hey, I'm going to have you fund the FDA that's making the decisions on whether you get cleared. People would say that sounds ridiculous. That's what we do. It's 45 percent of the FDA budget is from pharma. So I agree with I'm not sure you're supposed to make a trading move based upon the last 24 hours, even though people have made those moves. And I would make an argument, and I don't mean to, I'm not even sure that this group knows what their views are.
33:27I think there are some fundamental views on where Americans have, and how they've been treated in the past, and an ability to choose, and certain corporates that have dominated. I don't think there's any disputing that. But I would bring it back to the trade, and I would talk about Tim's Pfizer here to say, is Pfizer really getting sold off again on vaccines, when in fact we've already sold off their vaccine business 15 times? And if you look at where they were, it was a$54 billion business back in 21. I think we know why. And by 26, it's at least projected to be, even before this news, to be a$22 billion business, whereas oncology is growing 60 percent.
34:01So, you know, those are the kind of opportunities, I think, for investors and for traders that I think this kind of volatility is kind of interesting over the last few days. Julie, are you a buyer of this weakness in health care? Yeah, I mean, absolutely. What a luxury we have to be able to turn down all of the scientific advancements that we've had in the last, I don't know, 100 years that have saved millions of lives. It's ridiculous. I really genuinely believe that we will continue to see innovation. It's just a major resource that we have in the U.S. for GDP and such large and important industries.
34:33So I think this is a little bit overextended hype and probably a lot of the anxiety of what people are feeling with some of these appointments. I think that's manifesting emotionally in this market. All right. Coming up, the technical setup that could lead to nuclear gains for uranium producer Cameco and what is next for the Red Hot Industry Plus. A rip-roaring round of what to expect from retail earnings next week, whether you should shop or drop these names right after this.
35:10welcome back to fast money cameco hovering near all-time highs despite the pullback in green energy stocks earlier this month one trader says the stock is at a major inflection point the chart master out with a note today saying that both short and long-term charts show the potential to go even higher his price target is 65 and that is 20 percent higher from here. Tim, you've been a supporter of the stock. And it's been volatile. And in fact, you could have bought intraday highs in January in Cameco somewhere with a five handle, a 50 handle, that is. And I think, you know, you look at where the stock is now, there's been a lot of news flow and there's been a lot of earnings.
35:47And there's a dynamic that this is not a cheap company. But when I look at the news and the headlines today that Russia is restricting enriched uranium to the United States, no surprise there either. But it is a dynamic that is setting the table. I also just think the conversation we're having about utilities all the time and the grab for power, there are utilities out there that are short uranium. And I think that's part of the story. And when you think about the uranium story, what's the biggest problem with nuclear reactors is that it takes too long to build. But if you have a Trump presidency that lowers that regulatory hurdle, then instead of 20 years to build a new reactor, maybe you can bring that cut into half.
36:24Because in other countries, it takes a quarter of that to bring a new power plant online. And if you're a believer in the AI story, you need to be a believer in the energy side of the story as well. You have to. Yes. Right. We need to solve that if this AI story is going to continue apace. Yeah. Julie, where are you on uranium? Yeah, no, I agree. I think all of the things are conspiring to need more power on the grid, and it can't just be renewable power. It really needs to be baseload power. And this is the cleanest and clearest solution. Even though we've heard about the Trump agenda being very anti-climate, any movement towards any nuclear power is going to be very beneficial for the climate for sure.
37:05Coming up, retail earnings putting pedal to the metal next week. What to expect from Walmart, Target, TJX, and more. That's next. And here's a sneak peek at the Kramer cam. Jim is chatting exclusively with the Dover CEO. Catch the full interview, top of the hour, on Mad Money. More Fast Money in two.
37:29Welcome back to Fast Money. A number of consumer names reporting next week. Walmart kicking things off on Tuesday, followed by Target, TJX, and Gap. In the days that follow, the numbers come just ahead of the holiday shopping season. Ho, ho, ho. CBC's Courtney Reagan is here in-house for a preview of what is to come. A big week, Court. Yeah, it's a really big week, of course, and ahead of Black Friday, Thanksgiving. You know, just a little bit happening in retail right now. I mean, overall, market watchers, though, of course, want to know if this uncertainty that executives have been talking about for months and quarters now has alleviated at all in these early days of the fourth quarter.
37:58now that the U.S. election is over. Beyond that, of course, like Mel says, it's all about the holiday forecast. Walmart is the biggie, of course. It's always a proxy for the broader consumer environment. The street's expecting a continuation of positive comparable sales somewhere above 4%. Walmart has spent billions of dollars investing in technology and employees. It's really seemingly paid off. Shares are up 61 % year-to-date for Walmart. But investors also care a lot about what Walmart executives will ultimately say about the consumer. Now, consensus for Target, we expect comp sales to grow about 1.5 % in the quarter.
38:29That would be the second straight quarter of gains after four straight quarters of falling sales. B of A, though, says not so fast. We're not sure sales grew. We think that Target might have been a victim of sales deceleration in the quarter based on some data they're looking at. Placer.ai data does show a slight uptick, though, in Target store traffic for the quarter, so it could be close. Home Depot's results exceeded expectations, but they're still fighting to regain sales growth. Expect a similar story from Lowe's, which has posted financials slightly weaker than its larger competitor, as of late at least.
38:59Placer AI data does show a 4 % drop in Lowe's store traffic in the third quarter. Now, Citi and TD Cowan, among those endorsing TGX ahead of results, it's hit all-time highs this week. It just seems to be a name that keeps hitting on all lists, almost regardless of what's going on in the macro environment. The share performance hasn't been as strong as Walmart, but it's also very steady as she goes, too. I guess there's one fewer week, right, in this holiday shopping season because Thanksgiving is so late. But Black Friday has started. I mean, it started last week. It started last week. And also, I mean, to be fair, those October sales, which were captured in some of that retail sales data this year.
39:31But if you look at year over year, they were in it last year, too. So I think that really elongates the season and you just get those sales whenever you can get them. But it does sort of confuse the numbers, I think, a little bit because of that early start. But we will be able to get a read at least through weeks, right? Exactly. In terms of intent to spend. Exactly. Exactly. Exactly. Depending on the amount of detail that we're going to get on those October sales, which I know is something, you know, we all want to ask. It just depends on how much they want to reveal to the granular effect of those sales particular in that period of quarter.
39:58So how has the game really changed? It used to be Black Friday and then Cyber Monday and now cyber's anytime, right? I know. How do we. Hold on. Have we begun? Is it time? It has. How are you getting emails about Black Friday? Like Black Friday? So I'm already late. Did I miss you? Yes, you are. I mean, I'm going to get these numbers wrong, but I think it's like 40-some percent of Americans have already bought at least one gift for the holiday season. I bought a lot. I have, yeah. Yeah, I have, too. I mean, it's working. So I think how it's changed is, yeah, it's a little bit all the time, but I think it's a little bit earlier.
40:26It's a little bit more spread out. I think because you can buy online now and the fact with buy online, pick up in stores, sometimes you also see this really big, lumpy time right at the end of the season, which is making some retailers nervous this year, like Melissa says, because there's five fewer days. They're a little bit worried about the inventory having it in the right place at the right time, especially if people are waiting, since you had this early rush and then this lull and then maybe a big lumpy end. Yeah. In terms of tariffs, that's going to be a huge topic on the conference calls.
40:55What is the ability of these retailers to stockpile? I mean, you don't want to have inventory, but yet you don't want to pay the tariffs. I mean, what do you do in this situation? I know, exactly. You know, and I don't know that anyone's opening their playbooks to us yet. We've asked these exact questions. They're all sort of saying we're watching it, we're preparing. But if you talk to some of the smaller retailers, some of the non-publicly traded retailers that might tell you a little bit more, they're sort of saying, look, we can't really stockpile. It doesn't really make too much sense. I asked this exact question of someone that actually is a seller of Christmas trees.
41:23They make artificial Christmas trees. So it doesn't really make sense. I mean, we're looking right now into who we can help lobby us in D.C. to hopefully get categories exempt or hopefully this is just a negotiating tactic. But we can't really we can't really stockpile. We're just kind of crossing our fingers and hope this works. And many of these retailers, small or large, have been trying to diversify away from China, to be fair, before tariffs sort of 1.0 under that first Trump administration. But it takes a long time. And sometimes it's not worth it with the expense, the time, the expertise.
41:51It's hard to find somewhere else. Court, thank you. Always good to see you, Courtney Reagan. Coming up next, Final Trades.
42:05Time for the Final Trade. Let's go around the horn. Julie Beal. Again, I think this health care trade is overblown. West Pharmaceuticals well positioned. It's time to get busy holiday shopping. I'll tell you that. You are known, though, for leaving it to the very last minute. I have one year. He still has yet to do last year. Let's air this on national cable. I appreciate that. Let's blow this up with some uranium. CCJ. All right. No, but you're very resorted. I got it done. You got great power shop here. You're right to poem. Thank you. I'm good. All right. I'm with my girl, Julie Beal. Also, I think overblown.
42:42I like the IBB here. Steve Grasso. Applied Digital. So I looked at this because it's a smaller company, but NVIDIA gave them an injection, took a small take in it, and they're a customer of NVIDIA's, so I don't think NVIDIA's going to allow them to go out of business. Just taking a gamble on this thing. All right. Thanks for watching fast. Have a great weekend. Mad Money with you and Kramer starts right now.
43:11All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.
43:46To view the full Fast Money disclaimer, please visit cnbc.com forward slash fastmoneydisclaimer.
From the publisher
AI darling Nvidia gearing up to report results next week, and expectations are through the roof. What Wall Street is expecting out of those numbers, and how you can trade the chip giant. Plus Biotech, pharma, and all things healthcare related taking a dip as President-elect Donald Trump appoints Robert F. Kennedy Jr. to lead the Department of Health and Human Services. And a look into some of his previous advisors could give some insight on what to expect when he takes the helm.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
